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Abstract: Tissue Engineering as an emerging biotechnology sector aims at the in vitro regeneration of diseased 
tissues and promises to profoundly change medical practice, offering the possibility of regenerating tissues and 
organs instead of just repairing them (regenerative medicine). Improved healing processes and a higher quality 
of life are the expected results. This article gives an overview of different technologies for regenerative medicine 
and presents results of our own current applied research and development. A recent project was successfully 
closed with the development of a natural biomaterial for soft tissue oral defects. The establishment of an in vitro 
bioreactor system enabled us to simulate the mechanical and biological environment in a healing wound and to 
investigate the suitability of different implant materials for the oral tissue regeneration. Moreover, focusing the 
attention on an alternative method for  the  intervertebral disc  (IVD) regeneration, we established a new tissue 
engineered approach, based on the three-dimensional (3D) culture of autologous human IVD cells into a polyure-
thane (PU)-fibrin composite. IVD cells were able to proliferate and, thanks to the 3D conditions, to differentiate 
expressing  the  typical native  tissue markers. The development of an automated platform was the goal of an 
additional project, to standardize the cell culture technology, increase the bio-safety and reduce the production 
costs, moving tissue engineering nearer to clinical application. 
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Introduction
Age today no longer has the meaning it 
used to have. Because people live longer, 
the medical and scientific community is 
therefore expected to provide for good 
health and solutions to various degenera-
tive ailments. This is where regenerative 
medicine steps in and offers innovative 
treatments and cures. Tissue engineering 
provides the opportunity to regenerate 
impaired tissues (and organs, as a future 
perspective) using in vitro techniques or 
a combination of in vitro and in vivo pro-
cesses. Although this technology field was 
first defined by Langer and Vacanti[1] as 
early as 1993, the clinical application and 
commercialization of biological products 
are still in their initial phase. The inter-
disciplinary field of tissue engineering 
applies the principles of engineering and 
life sciences toward the development of 
biological substitutes that restore, main-
tain or improve tissue or organ function.[1] 
Several products, currently on the market, 
are suitable for skin substitution (e.g. Der-
magraft®, Advanced BioHealing, United 
States; Apligraf®, Organogenesis Inc., 
United States; Epicel®, Genzyme Biosur-
gery, United Kingdom), knee cartilage 
repair (autologous chondrocyte transplan-
tation, ATC by co.don AG, Germany; Car-
ticel®, Genzyme Biosurgery, United King-
dom) and a few for bone repair. Most of the 
products are relatively simple and consist 
of only one cell type. Others that are more 
advanced are under development or in 
clinical trials, such as bioartificial organs 
like urinary bladder (e.g. Neo-Bladder 
AugmentTM, Tengion, United States)[2] and 
liver,[3] or for cardiovascular diseases.[4] 
Even if several scientific and technical 
hurdles still need to be overcome (e.g. vas-
cularisation, controlled three-dimensional 
structure, coordinated action of different 
cell types), the use of stem cells, the im-
provement of the bio- and implant mate-
rials as well as the controlled release of 
bioactive signaling factors enhance the 
potential of tissue engineering technolo-
gies. Commercial expectations are high 
regarding the potential markets which 
tissue-engineered products could cover. 
Estimations are in the range of 4–400 bil-
lion Euro per year worldwide.[5]
Two Main Strategies: in vitro and in 
vivo
Cells, scaffolds and signaling factors 
represent the core of all tissue-engineering 
strategies. In addition the producing tech-
nologies, like bioreactor systems, applying 
perfusion and biomechanical stimulation 
are crucial. The basic idea is to recreate a 
structure able to respond to biological and 
mechanical signals, and to interact with 
the surrounding host tissue after the im-
plantation. Biomaterial scaffolds provide 
a critical means of controlling engineered 
tissue architecture and mechanical proper-
ties, functioning as a carrier for cells and 
biomolecules such as growth factors. The 
procedure of the in vitro strategy is a new 
functional tissue based on a biodegradable 
and resorbable scaffold, which is colonized 
in vitro with autologous cells of the patient 
and later implanted. As the cells grow and 
produce extracellular matrix (ECM) (Fig. 
1), the new tissue substitutes the scaffold 
that is gradually degraded, resorbed or me-
tabolized. Biological and technical experi-
ence have developed rapidly over the last 10 
years, but the legislation and regulations for 
the use of living cells for transplantation are 
restrictive and hurdles in the approval pro-
cess for biological products are huge.
The scaffold can also be implanted 
into the patient without cells. The acellular 
biomaterial with bioactive behavior will 
enhance the repair of the tissue, e.g. bone. 
The regenerative process will be performed 
by the body itself in vivo. This strategy is 
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balance, an in vitro testing system was 
established, able to mimic the mechanical 
and biological environment in a healing 
wound.
The bioreactor system was developed 
in our research group in cooperation with 
the Institute for Biomechanics of our uni-
versity. It is able to apply pressure and 
shear forces as well as medium perfusion 
to specimens (Fig. 2) and therefore mim-
ics the mechanical stresses of the human 
in vivo situation. Known characteristics 
of gingival connective tissue regeneration 
were incorporated in the development of 
the bioreactor.[9]
The results of the performed study in-
dicate that static conditions are not suit-
able for investigating the natural interac-
tion between cells and a biomedical device 
intended to be used for soft tissue grafting. 
Only mechanically stressed specimens 
displayed tissue specific characteristics 
like ECM assembly and expression of tis-
sue remodeling signals. Moreover, cell 
orientation of gingival fibroblasts differs 
between samples cultivated under static 
compared to dynamic cultivated ones (Fig. 
3). Cells are more compact and fill out the 
pores of the material while the cells grown 
on the biomaterial under static conditions 
are more randomly distributed and stay at-
tached to the fibers.[9]
Bioactive Factors Modulate Cell 
Responses
Not only biomaterials are able to guide 
tissue formation, also soluble factors can 
modulate remodeling processes. To inves-
tigate fibroblast behavior during 3D incu-
bation with different bioactive factors, an 
activity-determination assay was estab-
lished in our group. By using this assay, 
the impact of platelet derived growth factor 
was investigated concerning the ability to 
enhance fibroblast contraction potential. It 
was shown in a 3D collagen gel that the 
growth factor alone can stimulate gel con-
traction similar to the serum control (Fig. 
4). Together with other results this led to the 
conclusion that the platelet-derived growth 
factor is able to enhance tissue regenera-
tion and remodeling processes. Even com-
parative studies with factors from different 
suppliers can be performed and statisti-
cally significant differences occur.
Cell-based Therapies
A crucial point for the repair and resto-
ration of a tissue using tissue engineering 
techniques is that the biological substi-
tute has to perform the appropriate physi-
ologic/metabolic duties. Hence, the best 
approach seems to be represented by the 
followed in different graduations. The 
simplest one is the introduction of a bio-
material which has the same physical and 
mechanical properties as the surrounding 
tissue. The body’s own cells will populate 
the material, degrade it and thereby aug-
ment the impaired tissue. Obtaining au-
thorization for the clinical use of acellular 
materials is not a major problem. For this 
reason most industrial companies prefer 
to develop biocompatible and degradable 
biomaterials for tissue integration.
In more complex situations where the 
defects are too large or too difficult to re-
generate, signaling factors have to be inte-
grated into the scaffold in order to stimulate 
the tissue regeneration in vivo. Products like 
InductOS™ (Medtronic Inc., United States) 
and Osigraft® (Stryker, United States) are 
based on a matrix in combination with bone 
morphogenetic factors such as BMP-2 or 
BMP-7. These molecules are able to induce 
the differentiation of precursor cells to osteo-
blasts, building up the newly formed bone. 
The latest and most promising efforts 
have been undertaken by using the organism 
itself as a bioreactor system. Dvir et al.[6] per-
formed a pre-vascularization of engineered 
cardiadic patch in the omentum for seven 
days before transplantation into rat hearts.
Our research group of the Zurich Uni-
versity of Applied Sciences follows cell-
based as well as acellular strategies for 
tissue augmentation and replacement. 
Several projects mostly supported by CTI 
are running. Some of them revolve around 
cell-based therapy for intervertebral disc 
degeneration and for liver regeneration. 
Additional tissue engineering projects fo-
cus on the development of biomaterials, 
e.g. soft tissue and bone substitutes. 
Development of Biomimetic 
Materials
Biomaterials in tissue engineering ap-
plications are used to support and guide 
the growth of cells in specific two- or 
three-dimensional (2D or 3D) structures. 
They take over the task of the ECM, which 
naturally provides cells with a supportive 
framework of proteins, carbohydrates and 
signalling molecules. The ideal biomate-
rial should mimic the ECM as closely as 
possible and reveal similar physical prop-
erties. Moreover, it should be degradable, 
safe and easily available at acceptable cost. 
Interdisciplinary cooperation is the secret 
to success, combining various aspects of 
medicine, material science, engineering 
and biology.
One of our recently completed projects 
resulted in the successful development of 
a natural substitute material for soft tissue 
restoration in the oral cavity. Especially 
in dental medicine, the augmentation and 
build-up of hard and soft tissue is an im-
perative issue for implant integration and 
functional feasibility.
Soft tissue management in the oral cav-
ity has become one of the major challenges 
in cranio-maxillofacial surgery. In order to 
improve both functional and esthetical out-
comes, autogenous soft tissue grafts, such 
as the free gingival graft (FGG) or the sub-
epithelial connective tissue grafts (SCTG), 
are still considered to be the gold standard 
and are broadly used for various indica-
tions.[7] The development of biomaterials 
intended to augment soft tissue volume in 
the oral cavity is challenging. The efficacy 
testing of different prototypes requires so-
phisticated and expensive animal models 
and numbers, but control over the mechan-
ical forces is still lacking. Consequently, 
the transfer of animal data to human beings 
may be difficult. Gingival cells of the con-
nective tissue are exposed to various and 
complex mechanical stresses during masti-
cation, speech, and orthodontic movement. 
Especially during the procedure of wound 
healing, internal and external forces arise, 
creating pressure upon the newly formed 
tissue. A graft substitute has to withstand 
these forces in order to augment gingival 
soft tissue and must face the gold standard, 
which is the autogenous tissue graft.[8] 
In our study a collagen sponge, which 
is under development by the dental device 
company Geistlich Pharma AG was inves-
tigated. [9] Although collagen materials are 
commonly used as implantable materials 
in different fields in periodontology and 
implantology,[10] low mechanical strength 
and fast degradation are unlikely to with-
stand the mechanical forces that are ap-
plied during soft tissue volume augmenta-
tion. The mechanical stability of collagen 
sponges can be improved by stiffening the 
matrix body, but increased stiffening may 
compromise tissue integration.[11] There-
fore the right balance between mechanical 
stability and uneventful soft tissue heal-
ing needs to be attained. To evaluate this 
Fig. 1. Detection of collagen type I on a human 
primary fibroblast. Immunhistochemical 
staining of collagen type I indicates the 
distribution of the ECM protein on the cell 
surface. Collagen type I is stained red, cell 
nucleus in blue.
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use of autologous cells that avoid inflam-
matory reactions in the patient and carry 
out the biological tissue-specific program. 
Cell therapies currently being investigated 
include the use of stem cells, cells isolated 
from the tissue or organ that has to be re-
paired, and established cell lines or cells 
derived from modified animals. Several 
pre-clinical models as well as clinical ap-
plications include chondrocytes for carti-
lage repair,[12] keratinocytes and/or dermal 
fibroblasts for burn and wound repair,[13] 
myocytes for myocardial repair,[14] and 
Schwann cell transplantation to restore 
myelin in CNS lesions.[15] 
Recently in our laboratory we estab-
lished a new approach for the regeneration 
of the intervertebral disc (IVD), based on 
the 3D culture of autologous human disc 
cells into a polyurethane (PU)-fibrin com-
posite for the regeneration of the nucleus 
pulposus (NP) tissue at an early-stage of 
degeneration.[16] In our system the IVD 
cells were seeded on a macroporous scaf-
fold, such as PU particles (kindly provided 
by polyMaterials AG, Germany), and later 
encapsulated into an injectable hydrogel, 
the fibrin glue Tissucol (Baxter, Switzer-
land). Several studies performed on struc-
tures composed from cells embedded in 
hydrogels revealed the correct ECM for-
mation, but did not supply the required ini-
tial stability to the implant. The combina-
tion of the PU spheroids and its embedding 
in the fibrin glue was realized in order to 
provide the composite with the requested 
mechanical resistance and to recreate in 
vitro a 3D environment for cell differ-
entiation. The purpose was to develop a 
composite on which the IVD cells could 
initially adhere, proliferate and have the 
time, after the implantation, to synthesize 
the ECM proteins in order to re-establish 
the original IVD conditions.[16]
Looked at in detail, the human pri-
mary IVD cells, fresh isolated from bi-
opsies, were 2D expanded, seeded on PU 
spheroids, let to adhere (cell adhesion ef-
ficiency: 78±9.6%) and proliferate for few 
days. The cell-seeded particles were then 
encapsulated into fibrin and the cell dis-
tribution was analyzed up to 14 days, us-
ing 4’-6-diamidino-2-phenylindole (DAPI) 
staining (Fig. 5C–F). During the culture 
period observed, the cells were able to 
proliferate and to migrate from the PU 
spheroids to the fibrin. At day 14 IVD 
cells reached a homogenous distribution 
on the glue (Fig. 5E, F) as the cells directly 
mixed in the fibrin and cultivated under 
the same conditions as PU-fibrin compos-
ites for two weeks (Fig. 5G, H). The IVD 
cells, migrating from the PU particles to 
the fibrin, switched from a macroporous 
(a 2D situation for the cell size) to a mi-
croporous environment, simulating 3D in 
vivo conditions. The cell proliferation, ob-
Fig. 2. Bioreactor set-
up with six reaction 
chambers made of 
stainless steel and a 
motor for horizontal 
movement in the 
core of the chamber. 
Pressure forces are 
applied via compressed 
air on a silicone 
membrane. Biomaterial 
e.g. a collagen sponge 
seeded with human 
cells can be placed 
in the centre of each 
chamber.
Fig. 3. Cultivation condition essentially modulates cellular growth on a biomaterial. Human primary 
fibroblasts were grown under (A) dynamic conditions in a bioreactor and (B) under static conditions in 
a cell culture plate on a collagen sponge material. Green fluorescence indicates vital cells.
Fig. 4. Human gingival 
fibroblasts mediate 
the percentage of gel 
contraction. Collagen 
gels incorporating 
gingival fibroblasts are 
contracted to different 
extents in the presence 
of bioactive factors 
during an incubation 
period of 4 d. The most 
potent reagent shows 
the most extensive 
contraction.
Incubation [d]
Pe
rc
en
ta
ge
 o
f g
el
 c
on
tr
ac
tio
n 
[%
]
Swiss Biotech  CHIMIA 2010, 64, No. 11  811
typic characterization analyses (gene ex-
pression studies) confirmed the differen-
tiation of the IVD cells onto the PU-fibrin 
composites in vitro.[16]
Our experiments demonstrated the ca-
pability of human IVD cells to grow, ex-
press ECM proteins and re-differentiate 
onto PU-fibrin structures, suggesting the 
suitability of our model for disc regenera-
tion.
Automation – A Key Prerequisite 
for Clinical Application
It is in the nature of biological prod-
ucts that they vary. Primary cell isolation 
and cultivation involve many experience-
based steps such as surgical tissue collec-
tion, enzymatic digestion of the tissue, cell 
culture and analysis. In addition, the varia-
tion among patients’ biopsies impedes the 
standardization of the procedure and there-
fore experienced experts are necessary.[17] 
To ensure an effective, reproducible and 
affordable production process and to over-
come, or at least minimize, the hurdles in 
the approval process, a standardized and 
automated procedure to deliver cells and 
tissues is crucial.
In a recently completed project we real-
ized an automated tissue and cell process-
ing platform based on the Liquid Handling 
Robot Freedom EVO®150 (Tecan®, Swit-
zerland) (Fig. 7). We were able to isolate 
and to proliferate human primary interver-
tebral disc cells in a fully automated way. 
We could clearly show that the automated 
process was at least as good as the manual 
process or even better. In situ confluence 
measurement, giving information on cell 
growth, allowed automated process con-
trol. Furthermore, the differentiation of the 
cells was determined by immunofluores-
cent staining of specific markers automati-
cally analyzed with an integrated micro-
scope. The results have been submitted for 
publication in Journal of the Association 
for Laboratory Automation.
The integrated quality control and pro-
cess decision permits the standardization 
of a complex tissue engineering process. 
The innovation of this robot is a key pre-
requisite for future clinical application of 
tissue engineering. This automation is a 
major leap forward in bringing tissue en-
gineering technologies from the bench to 
the bedside.
Conclusion: “The Future of 
Medicine is Regenerative”
Regenerative medicine is one of the 
great hopes of the future for the treatment 
of organ damage, cancer and degenerative 
diseases. Our institute at the Zurich Uni-
versity of Applied Sciences and Biotechnet 
Fig. 5. DAPI stained cryosections of PU-fibrin composites and fibrin structures. Blanks: (A) 
PU-fibrin and (B) fibrin matrix without cells. Cell expansion and distribution into the PU-fibrin 
structure after 3 d (C), and 14 d (E) observed by fluorescence microscopy, and (D, F) overlay with 
light microscopy. (G) Cell distribution into the fibrin after 14 d culture observed by fluorescence 
microscopy and (H) overlay with light microscopy (20x magnification). 
served with DAPI staining, was confirmed 
from the DNA content quantification (Fig. 
6A). The DNA amount increased through-
out the culture, reaching a DNA value of 
3.27±0.86 mg after 7 d (2-fold vs. 3 d 
cultures) and of 3.58±0.79 mg after 14 d 
(Fig. 6A). Moreover, considering the im-
portance of the ECM in a healthy disc, the 
expression of collagen and glycosammi-
noglycans (GAG) was analyzed. The col-
lagen showed a significant increase in the 
second week of culture (Fig. 6B), while a 
constant GAG amount was detected over 
the period analyzed (Fig. 6C). The pheno-
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of Switzerland, the national consortium of 
biotechnology, contribute to the exciting 
development of these technologies by their 
activities in research, development and the 
education of students.
Painting too bright a picture of the po-
tential of tissue engineering will probably 
not help the development and the creation 
of confidence in this innovative technol-
ogy. To fulfill the promise of tissue en-
gineering, especially to construct in vitro 
human organs, several challenges relating 
to scientific, technological and also society 
issues need to be met. However, in the me-
dium to long term, the manifold research 
activities will result in the development of 
novel products to fight diseases for which 
no treatment is available today.
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